Is it safe to use tizanidine together with fluoxetine (Prozac) 60 mg daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, tizanidine should NOT be used with fluoxetine (Prozac) 60 mg daily—this combination is contraindicated.

The concurrent use of tizanidine with fluoxetine is contraindicated due to severe and potentially life-threatening drug interactions. 1, 2

Why This Combination Is Dangerous

Fluoxetine is a potent CYP1A2 inhibitor, and tizanidine is primarily metabolized through the CYP1A2 enzyme pathway. When these medications are combined:

  • Tizanidine clearance is significantly reduced, leading to dramatically elevated plasma concentrations 1
  • Severe hypotension, bradycardia, and excessive sedation can occur 1, 2
  • The FDA drug label for tizanidine explicitly states this combination is contraindicated 2

Evidence of Severe Interaction

Research demonstrates the magnitude of this interaction:

  • Fluvoxamine (a similar SSRI and CYP1A2 inhibitor) increased tizanidine exposure by 33-fold (range 14- to 103-fold), with peak concentrations increased 12-fold 3
  • This resulted in systolic blood pressure dropping to 80 mm Hg or less—an alarming and potentially dangerous finding 3
  • The elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours 3
  • All pharmacodynamic variables showed significant worsening, including dangerous drops in blood pressure and heart rate 3

While fluoxetine is a weaker CYP1A2 inhibitor than fluvoxamine, it still poses significant risk. A disproportionality analysis of FDA adverse event reports found elevated reporting odds ratios for hypotension when tizanidine was combined with CYP1A2 inhibitors 4.

Clinical Implications

The guideline consensus is clear: Tizanidine clearance is significantly reduced when given concomitantly with fluvoxamine and is hence contraindicated. Significant hypotension, bradycardia, and sedation can occur when given with other CYP1A2 inhibitors 1.

Common Pitfalls to Avoid:

  • Do not assume "monitoring" makes this combination safe—the interaction is too severe and unpredictable
  • Do not reduce tizanidine dose thinking this mitigates risk—even small doses can cause dangerous effects when metabolism is blocked
  • Remember that fluoxetine has a very long half-life (4-6 days for fluoxetine, 4-16 days for its active metabolite norfluoxetine), so the interaction risk persists for weeks after stopping fluoxetine 5

What To Do Instead

If muscle relaxation is needed in a patient taking fluoxetine 60 mg daily:

  1. Consider alternative muscle relaxants that are not metabolized by CYP1A2:

    • Baclofen (different mechanism, no CYP1A2 interaction)
    • Cyclobenzaprine (though structurally related to TCAs, may have other considerations)
  2. If switching from fluoxetine is considered, allow at least 5 weeks after stopping fluoxetine before starting tizanidine due to the long half-life of fluoxetine and its active metabolite 5

  3. If tizanidine is essential, consider switching from fluoxetine to an antidepressant that does not inhibit CYP1A2 (e.g., sertraline, citalopram, escitalopram) and allow adequate washout time

The risk of severe hypotension, syncope, falls, fractures, and cardiovascular collapse makes this combination unacceptable in clinical practice 3, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.